AB-329

News alerts, weekly reports and conference planners

Company:

Baoyuan Biopharma, Daiichi Sankyo

Drug class:

AXL inhibitor

Related drugs:

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + AB-329 Sensitive: C3 – Early Trials gefitinib + AB-329 Sensitive : C3	gefitinib + AB-329 Sensitive: C3 – Early Trials gefitinib + AB-329 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + AB-329 Sensitive: C3 – Early Trials osimertinib + AB-329 Sensitive : C3	osimertinib + AB-329 Sensitive: C3 – Early Trials osimertinib + AB-329 Sensitive : C3

Associations
(2)